Polymeric nanoparticles and a process of preparation thereof
The present invention relates to the field of nanotechnology, in particular, to the production of biodegradable polymeric nanoparticles. The present invention provides a biodegradable polymeric nanoparticle made up of a block copolymer and a process for producing the same. The nanoparticles are produced without the use of any emulsifiers and have a size ranging from 30-120 nm. The methods of controlling the drug loading capacity are disclosed along with the process of producing entity-loaded nanoparticles. Compositions comprising the nanoparticles and their use in therapeutics, diagnostics and theranostics are also disclosed.
1. A biodegradable polymeric nanoparticle formed of a block copolymer consisting essentially of poly(lactic acid) (PLA) chemically conjugated to a hydrophilic-hydrophobic block copolymer, wherein said hydrophilic-hydrophobic block copolymer consists essentially of PEG-PPG-PEG, the biodegradable nanoparticle is formed of the tetra block copolymer PLA-PEG-PPG-PEG, and the polymer of the biodegradable polymeric nanoparticle consists of one tetrablock copolymer.
2. The biodegradable polymeric nanoparticle of claim 1 , wherein the poly(lactic acid) (PLA) has an average molecule weight in the range of about 4,000 to about 90,000 g/mol.
3. The biodegradable polymeric nanoparticle of claim 1 , wherein the polyethylene glycol-polypropylene glycol-polyethylene glycol (PEG-PPG-PEG) has an average molecular weight in the range of about 4,000 g/mol to about 15,000 g/mol.
4. The biodegradable polymeric nanoparticle of claim 1 , wherein the size of the biodegradable polymeric nanoparticle is in the range of about 30 to about 120 nm.
5. The biodegradable polymeric nanoparticle of claim 1 , wherein the biodegradable polymeric nanoparticle is substantially free of emulsifier.
6. The biodegradable polymeric nanoparticles of claim 1 , wherein the biodegradable polymeric nanoparticle further comprises external emulsifier from about 0.5% to about 5% by weight.
7. The biodegradable polymeric nanoparticle of claim 1 , wherein the average molecular weight of the poly(lactic acid) block is from about 4,000 to about 90,000 g/mol, the average molecular weight of the PEG-PPG-PEG block is in the range of about 4,000 g/mol to about 15,000 g/mol, and wherein the biodegradable polymeric nanoparticle further comprises external emulsifier of about 0.5% to about 5% by weight.
8. The biodegradable polymeric nanoparticle of claim 1 , wherein the average molecular weight of the polylactic acid) block is less than or equal to about 16,000 g/mol, the average molecular weight of the PEG-PPG-PEG block is from about 4,000 g/mol to about 15,000 g/mol, and wherein the composition is substantially free of emulsifier.
9. The biodegradable polymeric nanoparticle of claim 1 further comprising a therapeutic agent.
10. The biodegradable polymeric nanoparticle of claim 9 , wherein the therapeutic agent is encapsulated, surface conjugated, or adsorbed on the biodegradable polymeric nanoparticle.
11. The biodegradable polymeric nanoparticle of claim 10 , wherein the therapeutic agent is selected from a group comprising small organic molecules, nucleic acids, polynucleotides, oligonucleotides, nucleosides, DNA, RNA, amino acids, peptides, proteins, antibiotics, low molecular weight molecules, chemotherapeutics, drugs, metal ions, dyes, radioisotopes, contrast agents and imaging agents.
12. The biodegradable polymeric nanoparticle of claim 11 , wherein the peptide is an anti-cancer peptide.
13. The biodegradable polymeric nanoparticle of claim 12 , wherein the anticancer peptide is either FSRSLHSLL (SEQ ID NO: 1) or any polypeptide substantially incorporating the FSRSLHSLL (SEQ ID NO: 1), and wherein the FSRSLHSLL (SEQ ID NO: 1) is in either the D or L-configuration.
14. The biodegradable polymeric nanoparticle of claim 12 , wherein the anti-cancer peptide is chemically modified with a hydrophobic polymer.
15. The biodegradable polymeric nanoparticle of claim 14 , wherein the anticancer peptide is either FSRSLHSLL (SEQ ID NO: 1) or any polypeptide substantially incorporating the FSRSLHSLL (SEQ ID NO: 1), wherein the FSRSLHSLL (SEQ ID NO: 1) is in either the D or L-configuration, and the hydrophobic polymer is poly(lactic acid).
16. The biodegradable polymeric nanoparticle of claim 12 , wherein the anti-cancer peptide is CQCRRKN (SEQ. ID NO: 2), a sequence from the MUC1-CD domain.
17. The biodegradable polymeric nanoparticle of claim 12 , wherein the anti-cancer peptide is AQARRKN(SEQ. ID NO: 4), a modified sequence from the MUC1-CD domain.
18. The biodegradable polymeric nanoparticle of claim 11 , wherein the therapeutic agent is a chemotherapeutic.
19. The biodegradable polymeric nanoparticle of claim 18 , wherein the chemotherapeutic is selected from the group consisting of paclitaxel, doxorubicin, pimozide, perimethamine, indenoisoquinolines, or nor-indenoisoquinolines.
20. The biodegradable polymeric nanoparticle of claim 1 , further comprising a targeting moiety selected from the group consisting of vitamins, small molecule drugs, ligands, amines, peptide fragments, antibodies, and aptamers.
21. The method of claim 16 , wherein the anticancer peptide is linked to a protein transduction domain.
22. The method of claim 21 , wherein the protein transduction domain is polyarginine.
23. The biodegradable polymeric nanoparticle of claim 12 , wherein the anti-cancer peptide is RRRRRRRRRCQCRRKN (SEQ. ID NO: 3) or RRRRRRRRRAQARRKN (SEQ. ID NO: 5).
24. The biodegradable polymeric nanoparticle of claim 1 , wherein the average molecular weight of the PLA is from about 45,000 g/mol to about 60,000 g/mol.
25. The biodegradable polymeric nanoparticle of claim 1 , wherein the size of the biodegradable polymeric nanoparticle is from about 10 nm to about 200 nm.